Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Grand Pharmaceutical Group Limited ( (HK:0512) ) is now available.
Grand Pharmaceutical Group Limited announced that its Treprostinil Injection, used for treating pulmonary arterial hypertension (PAH), has received a Drug Registration Certificate from China’s National Medical Products Administration. This approval marks a significant advancement in the company’s strategy to address rare diseases and enhance its market presence in the cerebro-cardiovascular emergency sector. The company has also entered into a strategic agreement with Shanghai ForeFront Pharmaceutical Co., Ltd., securing exclusive commercialization rights for several products, which will aid in building a global sales network and transforming into a comprehensive multinational pharmaceutical company.
The most recent analyst rating on (HK:0512) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Grand Pharmaceutical Group Limited stock, see the HK:0512 Stock Forecast page.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited operates in the pharmaceutical industry, focusing on the development and commercialization of treatments for rare diseases and cerebro-cardiovascular emergencies. The company has a strong product pipeline, including nearly 30 varieties in the cerebro-cardiovascular emergency segment and several products for rare diseases.
Average Trading Volume: 20,886,028
Technical Sentiment Signal: Buy
Current Market Cap: HK$30.88B
For an in-depth examination of 0512 stock, go to TipRanks’ Overview page.